A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC). Fifty-nine patients with unresectable progressive MTC per Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 within th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-01, Vol.22 (1), p.44-53
Hauptverfasser:	Schlumberger, Martin, Jarzab, Barbara, Cabanillas, Maria E, Robinson, Bruce, Pacini, Furio, Ball, Douglas W, McCaffrey, Judith, Newbold, Kate, Allison, Roger, Martins, Renato G, Licitra, Lisa F, Shah, Manisha H, Bodenner, Donald, Elisei, Rossella, Burmeister, Lynn, Funahashi, Yasuhiro, Ren, Min, O'Brien, James P, Sherman, Steven I
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biomarkers Carcinoma, Neuroendocrine - blood Carcinoma, Neuroendocrine - drug therapy Carcinoma, Neuroendocrine - pathology Disease Progression Female Humans Male Middle Aged Molecular Targeted Therapy Neoplasm Metastasis Neoplasm Staging Phenylurea Compounds - pharmacology Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Mas Quinolines - pharmacology Quinolines - therapeutic use Retreatment Thyroid Neoplasms - blood Thyroid Neoplasms - drug therapy Thyroid Neoplasms - pathology Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!